Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK: NICE Wins Argument Over Appraisal Of BioMarin Rare Disease Drug

BioMarin To Re-Engage With Process But Is Doubtful Of Outcome

Executive Summary

A decision by England’s High Court to reject claims that HTA body NICE acted unlawfully when evaluating BioMarin’s PKU treatment has quashed hopes that NICE’s Highly Specialized Technologies program will become more widely used to evaluate rare disease treatments. Lawyers representing a PKU patient are planning to appeal the judgement.

You may also be interested in...



UK: NICE’s Rare Disease Gatekeeping Comes Under The Microscope

A judicial review of how health technology appraisal body NICE decided which appraisal route BioMarin’s rare disease drug Kuvan would take could have lasting implications for future treatments.

Improve Access to RWD In Asia To Make RWE Viable

Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.

Italy To Consult On Pricing Transparency Requirements

Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel